- Datum28.04.2025
- Uhrzeit09:00 - 10:00 Uhr
- Veranstalter
XTB
Stefan Salomon
Moderator
Erasca Aktie
Verkaufen
Kaufen
Erasca Chart
Erasca Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Freestoxx | VK | |||||
| Nasdaq | VK | |||||
| Nasdaq Basic | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-1,41 %
Intraday
20,69 %
1 Woche
-5,41 %
1 Monat
-44,22 %
Seit Jahresbeginn
-25,53 %
1 Jahr
-83,51 %
3 Jahre
Passender Service zu Erasca
Webinar zu Erasca
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,010-3,450
- Jahrestief / Hoch ($)1,010-2,840
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Erasca
Keine Dividenden verfügbar
Termine von Erasca
Keine aktuellen Termine
Beschreibung
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
